A phase I trial evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of intravenously administered low-anticoagulant heparin (M6229) in critically ill sepsis patients

A phase I trial evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of intravenously administered low-anticoagulant heparin (M6229) in critically ill sepsis patients

Abstract Background Histones released in response to cellular injury are important mediators of organ failure and death in sepsis. Preclinical studies demonstrate that neutralization of histones in sepsis is associated with improved outcome. M6229 is a low-anticoagulant heparin able to neutralize hi...

Full description

Saved in:
Bibliographic Details
Main Authors: Niels van Mourik, Rombout B. E. van Amstel, Marleen A. Slim, Lonneke A. van Vught, Tom van der Poll, Joram Huckriede, Femke de Vries, Sjef J. de Kimpe, Raf Crabbé, Simone J. M. van Leeuwen, Peter F. Ekhart, Chris P. M. Reutelingsperger, Gerry A. F. Nicolaes, Alexander P. J. Vlaar, Marcella C. A. Müller
Format: Article
Language:English
Published: SpringerOpen 2025-08-01
Series:Intensive Care Medicine Experimental
Subjects:
Sepsis
Septic shock
M6229
Histones
Neutralization
Phase I
Online Access:https://doi.org/10.1186/s40635-025-00790-4
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s40635-025-00790-4

Similar Items